CD44 and malignant colon neoplasm: In the present study, to investigate the relationship between PRDX2 expression and CD133+CD44+ CCSCs, immunohistochemical (IHC) staining was conducted to determine the expression of PRDX2 in CD133(+)/CD44(+) and CD133(-)/CD44(-) colon cancer patients.